
  
    
      
        Introduction_NNP
        Tumor_NNP necrosis_NNS factor_NN (_( TNF_NNP )_) has_VBZ been_VBN implicated_VBN in_IN the_DT
        development_NN and_CC pathogenicity_NN of_IN infectious_JJ diseases_NNS and_CC
        autoimmune_JJ disorders_NNS ,_, such_JJ as_IN septic_JJ shock_NN ,_, arthritis_NN ,_, and_CC
        hypotension_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._. It_PRP plays_VBZ a_DT pivotal_JJ role_NN in_IN the_DT
        inflammatory_JJ cascade_NN and_CC ,_, together_RB with_IN IL-_NNP 1_CD and_CC IL-_NNP 6_CD ,_, has_VBZ
        been_VBN shown_VBN to_TO mediate_VB the_DT acute-phase_JJ response_NN [_NN 5_CD 6_CD ]_NN ._.
        Confirmation_NNP of_IN its_PRP$ significance_NN in_IN disease_NN comes_VBZ from_IN the_DT
        success_NN of_IN clinical_JJ trials_NNS using_VBG anti-_NN TNF_NNP therapy_NN to_TO treat_VB
        rheumatoid_NN arthritis_NN and_CC Crohn_NNP 's_POS disease_NN [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ._.
        Bacterial_NNP lipopolysaccharide_NN (_( LPS_NNP )_) ,_, or_CC endotoxin_NN ,_, is_VBZ
        found_VBN only_RB in_IN Gram-negative_NNP bacterial_JJ cell_NN walls_NNS ;_: it_PRP can_MD on_IN
        its_PRP$ own_JJ induce_VB the_DT acute_JJ inflammatory_JJ response_NN and_CC the_DT
        clinical_JJ characteristics_NNS associated_VBN with_IN sepsis_NN ._. After_IN
        administration_NN of_IN LPS_NNP ,_, TNF_NNP and_CC other_JJ inflammatory_JJ mediators_NNS
        are_VBP released_VBN [_NN 11_CD 12_CD ]_NN ._. Infusion_NN of_IN TNF_NNP initiates_NNS an_DT
        inflammatory_JJ process_NN leading_VBG to_TO a_DT phenotype_NN that_WDT is_VBZ
        indistinguishable_JJ from_IN bacterial_JJ sepsis_NN [_NN 13_CD 14_CD ]_NN ._.
        Recent_JJ work_NN on_IN tristetraprolin_NN (_( TTP_NNP )_) has_VBZ provided_VBN a_DT new_JJ
        perspective_NN on_IN the_DT regulation_NN of_IN TNF_NNP biosynthesis_NNS ._. TTP_NNP
        (_( also_RB referred_VBD to_TO as_IN NuP_NNP 475_CD ,_, TIS_NNP 11_CD ,_, or_CC GOS_NNP 24_CD )_) is_VBZ a_DT member_NN
        of_IN the_DT family_NN of_IN zinc-finger_JJ proteins_NNS that_WDT was_VBD originally_RB
        identified_VBN through_IN genetic_JJ screens_NNS designed_VBN to_TO identify_VB
        immediate_JJ early_JJ response_NN genes_NNS [_NN 15_CD 16_CD 17_CD 18_CD ]_NN ._. TTP_NNP was_VBD
        shown_VBN to_TO be_VB an_DT unusually_RB proline-rich_JJ protein_NN with_IN a_DT
        predicted_VBN molecular_JJ weight_NN of_IN 33_CD ._. 6_CD kDa_NN ._. Its_PRP$ name_NN derives_VBZ
        from_IN the_DT presence_NN of_IN three_CD PPPPG_NNP amino_JJ acid_NN repeats_VBZ that_WDT
        are_VBP conserved_JJ across_IN species_NNS ._. There_EX are_VBP two_CD Cys-_NNP Cys-_NNP Cys-_NNP His_PRP$
        (_( CCCH_NNP )_) zinc_NN fingers_NNS ,_, which_WDT are_VBP responsible_JJ for_IN RNA_NNP binding_JJ
        [_NN 17_CD 19_CD ]_NN ._. There_EX are_VBP no_DT studies_NNS of_IN the_DT subcellular_NN
        localization_NN or_CC the_DT regulation_NN of_IN expression_NN of_IN native_JJ TTP_NNP
        in_IN freshly_RB isolated_VBN cells_NNS or_CC tissue_NN ._. Transfection_NNP studies_NNS
        using_VBG nonhematopoietic_JJ cell_NN lines_NNS or_CC prolonged_JJ cell_NN culture_NN
        have_VBP suggested_VBN that_IN TTP_NNP is_VBZ found_VBN in_IN both_DT cytoplasm_NN and_CC the_DT
        nucleus_NN [_NN 20_CD 21_CD 22_CD 23_CD 24_CD ]_NN ._.
        A_DT deficiency_NN of_IN TTP_NNP is_VBZ associated_VBN with_IN a_DT profound_JJ
        proinflammatory_NN phenotype_NN ._. TTP-deficient_NNP mice_NNS exhibit_NN
        cachexia_NN ,_, with_IN dermatitis_NNS ,_, medullary_JJ and_CC extramedullary_JJ
        hyperplasia_NN ,_, erosive_JJ polyarthritis_NNS ,_, and_CC autoimmunity_NN with_IN
        autoantibodies_NNS [_NN 25_CD ]_NN ._. This_DT phenotype_NN is_VBZ similar_JJ to_TO that_DT
        observed_VBD in_IN mice_NNS that_IN overexpress_NNS TNF_NNP [_NN 26_CD ]_NN ._. In_IN agreement_NN
        with_IN these_DT data_NNS ,_, TTP-deficient_NNP mice_NNS were_VBD shown_VBN to_TO
        overproduce_NN TNF_NNP ,_, and_CC weekly_JJ injections_NNS of_IN a_DT neutralizing_VBG
        antibody_NN to_TO TNF_NNP eliminated_VBD the_DT predominant_NN features_NNS of_IN this_DT
        phenotype_NN ._. In_IN addition_NN ,_, mice_NNS with_IN the_DT double_JJ deletion_NN of_IN
        TTP_NNP and_CC TNF_NNP receptor_NN (_( TNFR_NNP )_) -_: 1_CD do_VBP not_RB manifest_JJ the_DT
        aggressive_JJ inflammation_NN observed_VBD in_IN TTP-deficient_NNP mice_NNS ._. In_IN
        contrast_NN ,_, mice_NNS deficient_NN in_IN TTP_NNP and_CC TNFR-_NNP 2_CD show_NN a_DT more_RBR
        severe_JJ phenotype_NN ,_, suggesting_VBG a_DT protective_JJ role_NN for_IN this_DT
        receptor_NN [_NN 27_CD ]_NN ._.
        The_DT increase_NN in_IN TNF_NNP biosynthesis_NNS in_IN TTP-deficient_NNP mice_NNS
        is_VBZ associated_VBN with_IN increased_VBN mRNA_NN stability_NN [_NN 23_CD ]_NN ._. TTP_NNP
        binds_NNS to_TO the_DT AU-rich_NNP element_NN (_( ARE_VBP )_) in_IN the_DT 3_CD '_POS untranslated_JJ
        region_NN of_IN TNF_NNP mRNA_NN ,_, which_WDT regulates_VBZ TNF_NNP mRNA_NN turnover_NN 
        in_IN vivo_NN [_NN 28_CD ]_NN ._. The_DT interaction_NN
        between_IN TTP_NNP /_NN TNF_NNP and_CC the_DT ARE_VBP promotes_VBZ the_DT turnover_NN of_IN TNF_NNP
        mRNA_NN ._. TTP_NNP also_RB regulates_VBZ the_DT stability_NN of_IN GM-CSF_NNP
        (_( granulocyte_NN /_NN macrophage-colony-stimulating_JJ factor_NN )_) mRNA_NN
        through_IN the_DT ARE_VBP ,_, and_CC therefore_RB TTP_NNP deficiency_NN is_VBZ associated_VBN
        with_IN increased_VBN production_NN of_IN GM-CSF_NNP and_CC with_IN myeloid_NN
        hyperplasia_NN ._. This_DT is_VBZ not_RB a_DT TNF-dependent_NNP effect_NN ,_, since_IN the_DT
        phenotype_NN is_VBZ not_RB affected_VBN by_IN the_DT removal_NN of_IN either_DT TNFR-_NNP 1_CD
        or_CC -_: 2_CD or_CC by_IN the_DT addition_NN of_IN TNF_NNP antibody_NN [_NN 27_CD ]_NN ._. Recent_JJ
        studies_NNS have_VBP suggested_VBN a_DT potential_JJ interaction_NN between_IN TTP_NNP
        and_CC both_DT IL-_NNP 3_CD and_CC IL-_NNP 8_CD via_IN the_DT ARE_VBP in_IN their_PRP$ mRNA_NN [_NN 29_CD 30_CD ]_NN
        ._.
        All_DT studies_NNS of_IN TTP_NNP expression_NN to_TO date_NN have_VBP relied_VBN on_IN
        transfected_JJ cells_NNS and_CC cell_NN lines_NNS ;_: there_EX have_VBP been_VBN no_DT
        studies_NNS on_IN the_DT localization_NN of_IN expression_NN of_IN human_JJ TTP_NNP ,_, or_CC
        on_IN its_PRP$ regulation_NN 
        in_IN vivo_NN or_CC in_IN freshly_RB isolated_VBN normal_JJ
        cells_NNS ._. To_TO examine_VB the_DT kinetic_JJ relation_NN between_IN TNF_NNP
        production_NN and_CC TTP_NNP expression_NN in_IN models_NNS of_IN septic_JJ shock_NN ,_, we_PRP
        developed_VBD an_DT intracellular_NN flow_NN cytometric_JJ assay_NN ._. By_IN this_DT
        method_NN ,_, expression_NN of_IN TTP_NNP was_VBD determined_VBN in_IN peripheral_JJ
        blood_NN leukocytes_NNS after_IN the_DT response_NN to_TO 
        in_IN vitro_NN stimulation_NN with_IN LPS_NNP ._. TTP_NNP
        was_VBD initially_RB upregulated_JJ in_IN all_PDT the_DT cells_NNS in_IN response_NN to_TO
        LPS_NNP ,_, as_IN shown_VBN by_IN flow_NN cytometry_NN and_CC confocal_NN microscopy_NN ._.
        The_DT contribution_NN of_IN TNF_NNP to_TO this_DT LPS-induced_NNP upregulation_NN
        was_VBD confirmed_VBN using_VBG a_DT humanized_JJ monoclonal_NN antibody_NN to_TO TNF_NNP ._.
        The_DT kinetics_NNS of_IN TTP_NNP production_NN was_VBD also_RB examined_VBN in_IN four_CD
        individuals_NNS infused_VBN with_IN LPS_NNP ._. After_IN 
        in_IN vivo_NN exposure_NN to_TO LPS_NNP ,_, the_DT initial_JJ
        rise_NN in_IN TTP_NNP expression_NN correlated_JJ with_IN the_DT plasma_NN TNF_NNP
        level_NN ._. We_PRP also_RB observed_VBD secondary_JJ increases_NNS in_IN some_DT
        individuals_NNS ,_, without_IN parallel_JJ increments_NNS in_IN TNF_NNP ._. These_DT
        observations_NNS suggest_VBP that_IN there_EX are_VBP multiple_JJ factors_NNS
        involved_VBN in_IN the_DT regulation_NN of_IN TTP_NNP ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Generation_NNP of_IN antihuman_NN TTP_NNP polyclonal_NN
          antibody_NN
          A_DT peptide_NN corresponding_JJ to_TO the_DT C_NNP terminus_JJ (_( amino_JJ acids_NNS
          302_CD -_: 328_CD )_) of_IN human_JJ TTP_NNP was_VBD synthesized_JJ ,_, purified_JJ by_IN HPLC_NNP ,_,
          and_CC coupled_VBN to_TO KLH_NNP (_( keyhole_NN limpet_NN hemocyanin_NN ;_:
          Macromolecular_NNP Resources_NNPS ,_, Fort_NNP Collins_NNP ,_, CO_NNP ,_, USA_NNP )_) ._.
          Anti-human_NNP TTP_NNP polyclonal_NN antibody_NN was_VBD generated_VBN by_IN
          immunization_NN of_IN New_NNP Zealand_NNP white_JJ rabbits_NNS with_IN the_DT
          KLH-coupled_NNP TTP_NNP C-_NNP terminal_NN peptide_NN (_( GeneMed_NNP ,_, San_NNP
          Francisco_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT rabbit_NN antiserum_NN obtained_VBN was_VBD
          affinity-purified_JJ by_IN passage_NN over_IN a_DT Sulfolink_NNP column_NN
          (_( Pierce_NNP ,_, Rockford_NNP ,_, IL_NNP ,_, USA_NNP )_) to_TO which_WDT disulfide_NN linkage_NN of_IN
          the_DT peptide_NN had_VBD been_VBN used_VBN to_TO immobilize_NN the_DT peptide_NN ._.
          Specificity_NNP in_IN Western_NNP blotting_VBG and_CC flow_NN cytometry_NN was_VBD
          evaluated_VBN by_IN detection_NN of_IN exogenous_JJ TTP_NNP in_IN transfected_JJ
          293_CD cells_NNS and_CC by_IN blocking_VBG this_DT activity_NN with_IN peptide_NN [_NN 24_CD
          ]_NN ._.
        
        
          Generation_NNP of_IN TTP_NNP vector_NN constructs_NNS
          Human_NNP TTP_NNP cDNA_NN was_VBD generated_VBN by_IN RT-PCR_NNP from_IN THP-_NNP 1_CD RNA_NNP
          and_CC cloned_VBN into_IN the_DT pcDNA_NN 3_CD ._. 1_CD His-_NNP C_NNP vector_NN (_( Invitrogen_NNP ,_,
          Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ,_, which_WDT encodes_NNS a_DT histidine_NN and_CC epitope_NN
          (_( EXPRESS-TAG_NNP )_) at_IN the_DT N-_NNP terminus_JJ of_IN the_DT protein_NN ._.
          Orientation_NNP of_IN the_DT cloned_VBN DNA_NNP and_CC the_DT integrity_NN of_IN the_DT
          DNA_NNP sequences_NNS were_VBD confirmed_VBN by_IN sequencing_VBG with_IN the_DT ABI_NNP
          Prism_NNP Dye_NNP Terminator_NNP Cycle_NNP Sequencing_NNP kit_NN (_( PerkinElmer_NNP ,_,
          Wellesley_NNP ,_, MA_NNP ,_, USA_NNP )_) ,_, and_CC searched_VBD against_IN the_DT published_VBN
          sequence_NN (_( TTP_NNP accession_NN no_UH ._. M_NNP 63625_CD )_) on_IN the_DT NCBI_NNP Database_NNP
          using_VBG the_DT BLAST_NN search_NN program_NN ._.
        
        
          Transient_NNP transfection_NN
          Human_NNP embryonic_JJ kidney_NN 293_CD cells_NNS (_( ATCC_NNP ,_, Manassas_NNP ,_, VA_NNP ,_,
          USA_NNP )_) were_VBD plated_JJ at_IN a_DT density_NN of_IN 160_CD ,_, 000_CD cells_NNS per_IN cm_NN 2_CD in_IN
          6_CD -_: well_RB plates_NNS (_( Costar_NNP ,_, Cambridge_NNP ,_, MA_NNP ,_, USA_NNP )_) ._. TTP_NNP (_( 1_CD μg_NN )_) or_CC
          the_DT TTP_NNP parental_JJ vector_NN pcDNA_NN 3_CD ._. 1_LS His-_NNP C_NNP (_( control_NN )_) was_VBD
          mixed_VBN with_IN 50_CD μl_NN of_IN serum-free_JJ RPMI_NNP (_( Roswell_NNP Park_NNP
          Memorial_NNP Institute_NNP )_) medium_NN ._. The_DT DNA_NNP was_VBD mixed_VBN with_IN 2_CD μl_NN
          of_IN Lipofectamine_NNP 2000_CD reagent_NN (_( Life_NNP Technologies_NNPS ,_,
          Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) in_IN a_DT total_JJ volume_NN of_IN 50_CD μl_NN of_IN
          serum-free_JJ RPMI_NNP per_IN cm_NN 2_CD of_IN cells_NNS ,_, incubated_JJ for_IN 3_CD hours_NNS ,_,
          and_CC followed_VBN by_IN the_DT addition_NN of_IN an_DT equal_JJ volume_NN of_IN media_NNS
          containing_VBG 20_CD %_NN fetal_JJ calf_NN serum_NN ._.
        
        
          Cell_NNP preparation_NN
          THP-_NNP 1_CD (_( generously_RB provided_VBN by_IN Dr_NNP P_NN Guyre_NNP ,_, Dartmouth_NNP
          Medical_NNP School_NNP )_) ,_, Jurkat_NNP (_( ATCC_NNP )_) ,_, and_CC 293_CD cell_NN lines_NNS were_VBD
          cultured_JJ in_IN RPMI_NNP complete_JJ medium_NN (_( CM_NNP )_) ,_, consisting_VBG of_IN RPMI_NNP
          1640_CD with_IN 10_CD %_NN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN ,_, 0_CD ._. 1_CD ml_NN
          of_IN sodium_NN pyruvate_NN ,_, 2_CD ._. 0_CD mmol_NN /_NN l_NN of_IN L-_NNP glutamine_NN ,_, 25_CD mmol_NN /_NN l_NN
          of_IN 1_CD M_NNP HEPES_NNP
          (_( N-_NNP 2_CD -_: hydroxyethylpiperazine-_NN N_NNP '_POS -_: 2_CD -_: ethanesulfonic_JJ acid_NN )_) ,_,
          0_CD ._. 1_CD mmol_NN /_NN l_NN of_IN nonessential_JJ amino_JJ acids_NNS ,_, 0_CD ._. 25_CD μg_NN /_NN ml_NN of_IN
          amphotericin_NN ,_, 50_CD μg_NN /_NN ml_NN gentamicin_NN (_( all_DT from_IN BioWhittaker_NNP ,_,
          Walkersville_NNP ,_, MD_NNP ,_, USA_NNP )_) and_CC 5_CD ×_NN 10_CD -_: 5_CD M_NNP 2_CD -_: mercaptoethanol_NN
          (_( Sigma_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) ._. Transfected_NNP and_CC
          nontransfected_JJ 293_CD cells_NNS were_VBD harvested_VBN using_VBG trypsin_NN
          (_( Life_NNP Technologies_NNPS )_) ,_, washed_VBD twice_RB with_IN CM_NNP ,_, resuspended_JJ to_TO
          a_DT concentration_NN of_IN 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN ml_NN ,_, and_CC fixed_VBD with_IN 4_CD %_NN
          methanol-free_JJ formaldehyde_NN (_( Polysciences_NNP Inc_NNP ,_, Warrington_NNP ,_,
          PA_NNP ,_, USA_NNP )_) ._. THP-_NNP 1_CD cells_NNS were_VBD incubated_JJ with_IN and_CC without_IN
          LPS_NNP ,_, 0_CD ._. 1_CD μg_NN /_NN ml_NN (_( 
          Escherichia_NNP coli_NNS 055_CD :_: B_NNP 5_CD ,_, Sigma_NNP )_) ,_, or_CC
          with_IN and_CC without_IN TNF_NNP (_( 100_CD U_NNP /_NN ml_NN )_) ._. In_IN addition_NN ,_, infliximab_NN
          (_( Remicade_NNP ®_NN )_) ,_, 100_CD μg_NN /_NN ml_NN (_( Centocor_NNP Inc_NNP ,_, Malvern_NNP ,_,
          Pennsylvania_NNP ,_, USA_NNP )_) ,_, was_VBD also_RB incubated_JJ with_IN and_CC without_IN
          LPS_NNP or_CC TNF_NNP to_TO determine_VB how_WRB much_JJ effect_NN TNF_NNP has_VBZ on_IN TTP_NNP
          induction_NN ._. Preliminary_JJ studies_NNS on_IN TNF-induced_NNP IκBα_NNP
          phosphorylation_NN determined_VBD the_DT optimum_JJ concentration_NN for_IN
          inhibition_NN with_IN infliximab_NN ._. After_IN incubation_NN ,_, the_DT cells_NNS
          were_VBD washed_VBN in_IN staining_VBG buffer_NN and_CC fixed_VBN with_IN 1_CD %_NN
          formaldehyde_NN ._.
          Leukocytes_NNP from_IN healthy_JJ donors_NNS were_VBD isolated_VBN by_IN
          dextran_NN sedimentation_NN from_IN heparinized_JJ peripheral_JJ blood_NN ._.
          In_IN some_DT experiments_NNS ,_, blood_NN was_VBD combined_VBN 1_CD :_: 1_CD with_IN RPMI_NNP CM_NNP
          and_CC incubated_JJ with_IN or_CC without_IN 0_CD ._. 1_CD μg_NN /_NN ml_NN LPS_NNP ._. At_IN the_DT
          indicated_VBN times_NNS ,_, blood_NN was_VBD mixed_JJ 1_CD :_: 1_CD with_IN 2_CD %_NN dextran_NN (_( 150_CD
          kDa_NN ;_: Polysciences_NNP )_) in_IN prewarmed_JJ RPMI_NNP and_CC left_VBN at_IN 37_CD °_NN C_NNP for_IN
          20_CD min_NN to_TO sediment_NN the_DT red_JJ blood_NN cells_NNS preferentially_RB ._.
          The_DT white-cell_JJ supernatant_NN was_VBD then_RB aspirated_JJ ,_,
          centrifuged_JJ ,_, and_CC mixed_JJ 1_CD :_: 5_CD with_IN CM_NNP ._. After_IN centrifugation_NN ,_,
          the_DT cell_NN pellet_NN was_VBD resuspended_JJ with_IN staining_VBG buffer_NN
          (_( prechilled_JJ to_TO 4_CD °_NN C_NNP )_) consisting_VBG of_IN phosphate-buffered_JJ
          saline_NN solution_NN with_IN 0_CD ._. 2_CD %_NN BSA_NNP and_CC 1_CD μg_NN /_NN ml_NN sodium_NN azide_NN ._.
          The_DT white_JJ cells_NNS were_VBD then_RB counted_VBN using_VBG Turks_NNPS solution_NN
          (_( 0_CD ._. 01_CD %_NN crystal_NN violet_NN and_CC 3_CD %_NN acetic_JJ acid_NN in_IN distilled_VBN
          water_NN )_) ,_, washed_VBN as_IN before_RB ,_, and_CC resuspended_JJ to_TO a_DT
          concentration_NN of_IN 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN ml_NN with_IN staining_VBG
          buffer_NN ._.
        
        
          Immunofluorescence_NNP staining_VBG
          To_TO detect_VB extracellular_NN antigens_NNS ,_, cells_NNS were_VBD pipetted_JJ
          into_IN a_DT 96_CD -_: well_RB polypropylene_NN plate_NN (_( Costar_NNP )_) ,_, and_CC the_DT
          plate_NN was_VBD centrifuged_JJ at_IN 400_CD 
          
            g_SYM 
           for_IN 5_CD min_NN ._. The_DT cells_NNS and_CC reagents_NNS were_VBD kept_VBN at_IN 4_CD °_NN C_NNP
          for_IN the_DT remainder_NN of_IN the_DT experiment_NN ._. The_DT supernatant_NN was_VBD
          aspirated_JJ ,_, and_CC the_DT cells_NNS were_VBD resuspended_JJ in_IN 6_CD %_NN human_JJ IgG_NNP
          (_( Sigma_NNP )_) in_IN staining_VBG buffer_NN to_TO block_VB nonspecific_JJ binding_JJ ._.
          Allophycocyanin_NNP (_( APC_NNP )_) -_: conjugated_JJ CD_NNP 14_CD (_( Becton_NNP ,_, Dickinson_NNP
          and_CC Co_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) was_VBD added_VBN ,_, and_CC the_DT cells_NNS were_VBD
          incubated_JJ for_IN a_DT further_JJ 20_CD min_NN in_IN the_DT dark_NN ._. The_DT cells_NNS
          were_VBD then_RB washed_VBN once_RB in_IN staining_VBG buffer_NN and_CC residual_JJ red_JJ
          blood_NN cells_NNS lysed_JJ with_IN FACS_NNP '_POS Lysing_NNP solution_NN (_( Becton_NNP
          Dickinson_NNP )_) ._. After_IN 5_CD min_NN the_DT cells_NNS were_VBD washed_VBN twice_RB with_IN
          staining_VBG buffer_NN and_CC fixed_VBN overnight_JJ in_IN 1_CD %_NN
          formaldehyde_NN ._.
          To_TO detect_VB intracellular_NN TTP_NNP ,_, fixed_VBN cells_NNS were_VBD washed_VBN
          twice_RB in_IN permeabilization_NN buffer_NN (_( consisting_VBG of_IN staining_VBG
          buffer_NN with_IN the_DT addition_NN of_IN 1_CD μg_NN /_NN ml_NN saponin_NN )_) ,_, centrifuged_JJ
          as_IN before_RB ,_, and_CC incubated_JJ for_IN 30_CD min_NN at_IN 4_CD °_NN C_NNP in_IN blocking_VBG
          buffer_NN ,_, consisting_VBG of_IN 3_CD %_NN IgG_NNP with_IN 3_CD %_NN nonfat_JJ powdered_JJ milk_NN
          for_IN leukocytes_NNS in_IN permeabilization_NN buffer_NN ._. The_DT plate_NN was_VBD
          centrifuged_JJ ,_, the_DT supernatant_NN was_VBD aspirated_JJ ,_, and_CC 3_CD ._. 8_CD μg_NN
          per_IN 5_CD ×_NN 10_CD 5_CD cells_NNS of_IN anti-_NN TTP_NNP rabbit_NN polyclonal_NN or_CC
          control_NN antibody_NN (_( DAKO_NNP A_DT /_NN S_NNP ,_, Glostrup_NNP ,_, Denmark_NNP )_) was_VBD added_VBN
          for_IN 45_CD min_NN more_RBR ._. After_IN incubation_NN ,_, the_DT cells_NNS were_VBD washed_VBN
          in_IN permeabilization_NN buffer_NN and_CC resuspended_JJ in_IN
          FITC-conjugated_NNP F_NNP (_( ab_NN '_'' )_) 
          2_CD (_( antigen-binding_JJ fragment_NN )_) donkey_NN
          antirabbit_NN IgG_NNP (_( 25_CD μg_NN /_NN ml_NN ,_, Jackson_NNP ImmunoResearch_NNP ,_, West_NNP
          Grove_NNP ,_, PA_NNP ,_, USA_NNP )_) for_IN 45_CD min_NN at_IN 4_CD °_NN C_NNP ._. Cells_NNP were_VBD washed_VBN with_IN
          permeabilization_NN buffer_NN and_CC then_RB with_IN staining_VBG buffer_NN ._.
          They_PRP were_VBD resuspended_JJ with_IN 1_CD %_NN formaldehyde_NN and_CC stored_VBD in_IN
          the_DT dark_NN at_IN 4_CD °_NN C_NNP until_IN analysis_NN ._. For_IN the_DT infliximab_NN
          inhibition_NN experiments_NNS ,_, a_DT goat_NN polyclonal_NN antibody_NN to_TO TTP_NNP
          was_VBD used_VBN (_( Santa_NNP Cruz_NNP Biotechnology_NNP Inc_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_)
          with_IN a_DT secondary_JJ swine_NNS antigoat_NN FITC-conjugated_NNP IgG_NNP
          antibody_NN (_( Sigma_NNP )_) ._. Preliminary_JJ experiments_NNS showed_VBD that_IN the_DT
          affinity_NN of_IN this_DT antibody_NN for_IN TTP_NNP was_VBD equivalent_JJ to_TO that_DT
          of_IN the_DT rabbit_NN polyclonal_NN antibody_NN ._.
          In_IN the_DT LPS_NNP infusion_NN study_NN ,_, TruCount_NNP ®_NN calibration_NN beads_NNS
          (_( Becton_NNP Dickinson_NNP )_) were_VBD quantitatively_RB added_VBN to_TO the_DT
          stained_JJ cells_NNS ._. Enumeration_NNP of_IN individual_JJ leukocyte_NN counts_VBZ
          was_VBD then_RB completed_VBN using_VBG Cell_NNP Quest_NNP ®_NN software_NN ._.
        
        
          FACS_NNP analysis_NN and_CC confocal_NN microscopy_NN
          Analysis_NNP by_IN flow_NN cytometry_NN was_VBD completed_VBN using_VBG a_DT
          FAC-SCalibur_NNP (_( Becton_NNP Dickinson_NNP )_) ._. Contaminants_NNP ,_, such_JJ as_IN
          red_JJ cells_NNS and_CC cell_NN debris_NN ,_, were_VBD removed_VBN by_IN forward_RB and_CC
          side_NN scatter_NN gating_VBG ;_: in_IN addition_NN ,_, CD_NNP 14_CD versus_CC side_NN
          scatter_NN was_VBD used_VBN to_TO create_VB gates_NNS to_TO differentiate_VB
          lymphocytes_NNS ,_, monocytes_NNS ,_, and_CC neutrophils_NNS ._. Fluorescein_NNP
          fluorescence_NN was_VBD detected_VBN through_IN the_DT FL-_NNP 1_CD channel_NN ,_, APC_NNP
          fluorescence_NN was_VBD assessed_VBN using_VBG the_DT FL-_NNP 4_CD channel_NN ,_, and_CC
          data_NNS were_VBD acquired_VBN and_CC analyzed_VBN using_VBG the_DT CellQuest_NNP
          ®_NN application_NN on_IN a_DT Power_NNP Macintosh_NNP G_NNP 3_CD computer_NN ._. For_IN each_DT
          sample_NN ,_, at_IN least_JJS 2000_CD monocytes_NNS were_VBD collected_VBN and_CC the_DT
          mean_JJ fluorescence_NN intensity_NN was_VBD evaluated_VBN ._. Calibration_NNP
          was_VBD done_VBN using_VBG Rainbow_NNP Microspheres_NNP (_( Spherotech_NNP Inc_NNP ,_,
          Libertyville_NNP ,_, IL_NNP ,_, USA_NNP )_) ,_, with_IN final_JJ values_NNS expressed_VBD as_IN
          the_DT milliequivalents_NNS of_IN soluble_JJ fluorescein_NN (_( MESF_NNP )_) [_NN 31_CD ]_NN
          ._.
          293_CD cells_NNS were_VBD sorted_VBN for_IN the_DT brightest_JJS FITC_NNP
          fluorescence_NN using_VBG a_DT FACStar_NNP Plus_NNP flow_NN cytometer_NN (_( Becton_NNP
          Dickinson_NNP )_) ._. Cells_NNP were_VBD collected_VBN into_IN tubes_NNS containing_VBG
          100_CD μl_NN fetal_JJ calf_NN serum_NN ,_, centrifuged_JJ ,_, and_CC resuspended_JJ in_IN
          1_CD %_NN formaldehyde_NN ._. The_DT cells_NNS were_VBD stored_VBN overnight_JJ at_IN 4_CD °_NN C_NNP
          in_IN the_DT dark_NN ._. TTP_NNP /_NN FITC-stained_NNP white_JJ blood_NN cells_NNS or_CC THP-_NNP 1_CD
          cells_NNS were_VBD centrifuged_JJ and_CC resuspended_JJ in_IN formaldehyde_NN as_IN
          for_IN 293_CD cells_NNS ._. Nuclear_NNP staining_VBG was_VBD done_VBN using_VBG propidium_NN
          iodide_NN 0_CD ._. 01_CD mg_NN /_NN ml_NN (_( Sigma_NNP )_) ._. For_IN confocal_NN microscopy_NN ,_, cells_NNS
          were_VBD pipetted_JJ from_IN the_DT base_NN of_IN the_DT settled_VBN cell_NN
          suspension_NN and_CC placed_VBN onto_IN a_DT glass_NN slide_NN with_IN Prolong_NNP
          ®_NN Antifade_NNP (_( Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_, OR_NNP ,_, USA_NNP )_) to_TO inhibit_VB
          quenching_VBG ._. The_DT cells_NNS were_VBD then_RB covered_VBN with_IN a_DT cover_NN slip_NN
          protected_VBN with_IN clear_JJ nail_NN polish_NN ._.
          Microscopy_NNP for_IN FITC-conjugated_NNP TTP_NNP analysis_NN was_VBD
          completed_VBN using_VBG a_DT BioRad_NNP MRC_NNP 1024_CD laser_NN scanning_VBG confocal_NN
          microscope_NN (_( BioRad_NNP ,_, Hercules_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Cells_NNP were_VBD
          scanned_JJ for_IN fluorescence_NN using_VBG the_DT 488_CD -_: nm_NN line_NN from_IN a_DT
          15_CD -_: mW_NN Kr_NNP /_NN Ar_NNP laser_NN and_CC two_CD photodetectors_NNS (_( 522_CD /_NN 32_CD -_: nm_NN
          dichroic_JJ for_IN FITC_NNP fluorescence_NN and_CC 585_CD -_: nm_NN longpass_NNS for_IN
          propidium_NN iodide_NN fluorescence_NN )_) ._. A_DT 63_CD ×_NN Plan-_NNP APO_NNP 1_CD ._. 4_CD NA_NNP
          objective_NN (_( Carl_NNP Zeiss_NNP Inc_NNP ,_, Thornwood_NNP ,_, NY_NNP ,_, USA_NNP )_) was_VBD used_VBN
          in_IN conjunction_NN with_IN an_DT iris_NNS setting_NN of_IN 2_CD ._. 5_CD ,_, which_WDT allowed_VBD
          for_IN detection_NN of_IN optical_JJ sections_NNS of_IN the_DT fluorescence_NN
          image_NN that_WDT were_VBD approximately_RB 0_CD ._. 5_CD μm_NN thick_JJ ._.
          Representative_NNP images_NNS were_VBD selected_VBN from_IN the_DT slices_NNS
          though_IN the_DT center_NN of_IN the_DT cells_NNS after_IN sectioning_VBG through_IN
          the_DT entire_JJ cell_NN ._.
        
        
          LPS_NNP infusion_NN
          Consenting_NNP volunteers_NNS were_VBD given_VBN an_DT intravenous_JJ bolus_JJ
          of_IN endotoxin_NN in_IN accordance_NN with_IN a_DT protocol_NN approved_VBN by_IN
          the_DT Institutional_JJ and_CC Scientific_NNP Review_NNP Boards_NNP of_IN the_DT
          Dartmouth-_NNP Hitchcock_NNP Medical_NNP Center_NNP and_CC Norris_NNP Cotton_NNP
          Cancer_NNP Center_NNP ,_, Lebanon_NNP ,_, NH_NNP ,_, USA_NNP ._. One_CD month_NN before_IN
          admission_NN and_CC again_RB just_RB before_IN admission_NN ,_, the_DT
          volunteers_NNS '_POS physical_JJ wellbeing_VBG and_CC health_NN were_VBD assessed_VBN ,_,
          and_CC current_JJ medications_NNS were_VBD noted_VBN ._. The_DT infusion_NN was_VBD
          conducted_VBN in_IN the_DT intensive_JJ care_NN unit_NN at_IN
          Dartmouth-_NNP Hitchcock_NNP Medical_NNP Center_NNP with_IN continuous_JJ
          supervision_NN for_IN the_DT first_JJ 12_CD hours_NNS ._. Blood_NNP pressure_NN ,_, heart_NN
          rate_NN ,_, and_CC body_NN temperature_NN were_VBD evaluated_VBN throughout_IN this_DT
          period_NN ._.
          Clinical_NNP Center_NNP reference_NN endotoxin_NN (_( CCRE_NNP )_) ,_, lot_NN O_NNP :_: 133_CD ,_,
          derived_VBN from_IN 
          E_NNP ._. coli_NNS (_( United_NNP States_NNPS Pharmacopeia_NNP
          Convention_NNP Inc_NNP ,_, Rockville_NNP ,_, MD_NNP ,_, USA_NNP [_NN 32_CD ]_NN )_) ,_, was_VBD injected_VBN
          intravenously_RB at_IN a_DT dose_NN of_IN 4_CD ng_NN /_NN kg_NN ._. Three_CD consecutive_JJ
          baseline_NN blood_NN samples_NNS were_VBD taken_VBN ,_, at_IN 15_CD ,_, 10_CD ,_, and_CC 5_CD min_NN
          before_IN infusion_NN ,_, and_CC samples_NNS were_VBD taken_VBN at_IN 0_CD ._. 45_CD ,_, 1_CD ,_, 2_CD ,_, 4_CD ,_,
          8_CD ,_, 12_CD ,_, 24_CD ,_, 48_CD ,_, and_CC 72_CD hours_NNS after_IN infusion_NN ,_, from_IN a_DT
          peripheral_JJ ,_, indwelling_VBG ,_, venous_JJ catheter_NN directly_RB into_IN a_DT
          heparinized_JJ syringe_NN (_( Becton_NNP Dickinson_NNP )_) ._. Blood_NNP was_VBD
          sedimented_JJ in_IN dextran_NN ,_, extracellularly_RB stained_JJ for_IN CD_NNP 14_CD ,_,
          and_CC fixed_VBD with_IN 1_CD %_NN formaldehyde_NN ._. The_DT cells_NNS were_VBD stored_VBN
          overnight_JJ at_IN 4_CD °_NN C_NNP and_CC then_RB stained_JJ for_IN intracellular_NN TTP_NNP ._.
          A_DT human_JJ TNF_NNP ELISA_NNP kit_NN (_( R_NN &_CC D_NNP Systems_NNPS ,_, Minneapolis_NNP ,_, MN_NNP ,_,
          USA_NNP )_) was_VBD used_VBN to_TO determine_VB the_DT concentration_NN of_IN TNF_NNP in_IN
          plasma_NN from_IN peripheral_JJ blood_NN ,_, in_IN accordance_NN with_IN the_DT
          manufacturer_NN 's_POS instructions_NNS ._. The_DT TNF-α_NNP standard_NN was_VBD made_VBN
          up_RP as_IN directed_VBN to_TO read_VB a_DT maximum_NN concentration_NN of_IN 1000_CD
          pg_NN /_NN ml_NN and_CC a_DT minimum_NN of_IN 15_CD ._. 6_CD pg_NN /_NN ml_NN ._.
        
        
          Statistical_NNP analysis_NN
          Analysis_NNP was_VBD by_IN one-way_JJ analysis_NN of_IN variance_NN (_( ANOVA_NNP )_)
          with_IN post_NN hoc_FW Bonferroni_NNP adjustment_NN (_( all-means_JJ
          comparison_NN )_) test_NN ,_, using_VBG the_DT Graphpad_NNP ®_NN Prism_NNP version_NN 3_CD ._. 00_CD
          for_IN Windows_NNP (_( Graphpad_NNP Software_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Optimization_NNP and_CC specificity_NN of_IN the_DT TTP_NNP polyclonal_NN
          antibody_NN
          To_TO determine_VB the_DT optimal_NN working_VBG concentration_NN of_IN the_DT
          TTP_NNP antibody_NN ,_, 293_CD cells_NNS transfected_JJ with_IN TTP_NNP were_VBD fixed_VBN ,_,
          permeabilized_JJ ,_, and_CC stained_JJ at_IN various_JJ concentrations_NNS of_IN
          antibody_NN or_CC IgG_NNP control_NN ._. There_EX was_VBD a_DT
          concentration-dependent_JJ increase_NN in_IN fluorescence_NN (_( Fig_NNP ._.
          1_LS a_DT )_) ,_, which_WDT was_VBD standardized_JJ using_VBG fluorescent_NN
          microspheres_NNS in_IN order_NN to_TO compare_VB different_JJ experiments_NNS
          and_CC cell_NN types_NNS [_NN 31_CD ]_NN ._. The_DT optimum_JJ concentration_NN of_IN
          antibody_NN was_VBD determined_VBN to_TO be_VB 3_CD ._. 8_CD μg_NN per_IN 5_CD ×_NN 10_CD 5_CD cells_NNS ,_,
          where_WRB the_DT intensity_NN curve_NN began_VBD to_TO flatten_VB ._. At_IN higher_JJR
          concentrations_NNS ,_, the_DT MESF_NNP value_NN for_IN the_DT control_NN sera_NN
          increased_VBD concordantly_RB ,_, indicating_VBG nonspecific_JJ binding_JJ ._.
          Specificity_NNP of_IN the_DT TTP_NNP antibody_NN was_VBD determined_VBN by_IN
          blocking_VBG with_IN the_DT identical_JJ peptide_NN sequence_NN used_VBN to_TO
          generate_VB the_DT polyclonal_NN antibody_NN ._. In_IN the_DT presence_NN of_IN
          blocking_VBG TTP_NNP peptide_NN ,_, at_IN concentrations_NNS either_DT 10_CD or_CC 50_CD
          times_NNS the_DT amount_NN of_IN TTP_NNP antibody_NN used_VBD ,_, the_DT detection_NN of_IN
          the_DT TTP_NNP protein_NN within_IN the_DT transfected_JJ cells_NNS was_VBD nearly_RB
          eliminated_VBN (_( Fig_NNP ._. 1_LS b_SYM )_) ._.
          Confocal_NNP sectioning_VBG of_IN transfected_JJ 293_CD cells_NNS showed_VBD
          that_IN the_DT presence_NN of_IN TTP_NNP protein_NN was_VBD primarily_RB in_IN the_DT
          cytoplasmic_JJ fraction_NN (_( Fig_NNP ._. 1_LS c_SYM )_) ._. Z_NN sections_NNS taken_VBN every_DT
          0_CD ._. 5_CD μm_NN through_IN the_DT cell_NN showed_VBD little_JJ ,_, if_IN any_DT ,_, TTP_NNP within_IN
          the_DT nucleus_NN ._. In_IN nontransfected_JJ 293_CD cells_NNS ,_, a_DT small_JJ amount_NN
          of_IN TTP_NNP was_VBD detected_VBN by_IN flow_NN cytometry_NN and_CC confirmed_VBN by_IN
          confocal_NN microscopy_NN ._. Transfected_NNP 293_CD cells_NNS expressed_VBD nine_CD
          times_NNS as_IN much_JJ TTP_NNP as_IN the_DT untransfected_JJ cells_NNS at_IN the_DT
          optimal_NN working_VBG concentration_NN of_IN antibody_NN ._. Preincubation_NNP
          of_IN the_DT nontransfected_JJ 293_CD cells_NNS with_IN TTP_NNP peptide_NN blocked_VBD
          the_DT activity_NN ,_, confirming_VBG its_PRP$ identity_NN ._. These_DT results_NNS
          confirmed_VBD our_PRP$ previously_RB published_VBN data_NNS in_IN which_WDT Western_JJ
          blot_NN analysis_NN showed_VBD that_IN TTP_NNP was_VBD localized_JJ in_IN the_DT
          cytoplasmic_JJ extract_NN of_IN 293_CD cells_NNS [_NN 24_CD ]_NN ._.
        
        
          Induction_NNP of_IN TTP_NNP in_IN the_DT THP-_NNP 1_CD cell_NN line_NN
          Since_IN TNF_NNP biosynthesis_NNS in_IN macrophages_NNS is_VBZ rapidly_RB
          triggered_VBN by_IN treatment_NN with_IN LPS_NNP ,_, the_DT effects_NNS of_IN this_DT
          endotoxin_NN on_IN TTP_NNP expression_NN were_VBD examined_VBN ._. THP-_NNP 1_CD cells_NNS ,_, a_DT
          human_JJ myelomonocytic_JJ cell_NN line_NN ,_, were_VBD incubated_JJ with_IN and_CC
          without_IN LPS_NNP (_( 0_CD ._. 1_LS μg_NN /_NN ml_NN )_) for_IN up_IN to_TO 24_CD hours_NNS ._. At_IN
          representative_NN time_NN points_NNS ,_, a_DT sample_NN was_VBD removed_VBN and_CC
          stained_JJ with_IN either_DT anti-_NN TTP_NNP or_CC the_DT IgG_NNP control_NN ,_, as_IN
          described_VBN in_IN Materials_NNPS and_CC methods_NNS ._. The_DT addition_NN of_IN LPS_NNP
          rapidly_RB increased_VBD the_DT expression_NN of_IN TTP_NNP by_IN THP-_NNP 1_CD cells_NNS
          (_( Fig_NNP ._. 2_LS a_DT )_) ._. Increases_NNS in_IN TTP_NNP were_VBD detectable_JJ 1_CD hour_NN after_IN
          stimulation_NN and_CC were_VBD still_RB evident_JJ in_IN the_DT cytosol_NN 4_CD hours_NNS
          after_IN LPS_NNP treatment_NN ._. Analysis_NNP of_IN the_DT cells_NNS by_IN confocal_NN
          microscopy_NN (_( Fig_NNP ._. 2_LS b_SYM )_) confirmed_VBD the_DT upregulation_NN and_CC
          indicated_VBD that_IN the_DT TTP_NNP was_VBD expressed_VBN intracellularly_RB ,_,
          relatively_RB homogeneously_RB but_CC confined_VBN to_TO the_DT cytoplasm_NN ._.
          These_DT data_NNS show_VBP that_IN LPS_NNP stimulation_NN rapidly_RB increases_VBZ
          human_JJ TTP_NNP protein_NN expression_NN in_IN the_DT cytoplasm_NN ._. The_DT
          kinetics_NNS of_IN induction_NN by_IN LPS_NNP parallels_NNS that_WDT seen_VBN with_IN TTP_NNP
          mRNA_NN in_IN bone-marrow-derived_JJ murine_NN macrophages_NNS [_NN 23_CD ]_NN
          ._.
        
        
          In_IN vitroTTP_NN induction_NN with_IN LPS_NNP in_IN peripheral_JJ blood_NN
          leukocytes_NNS
          Modulation_NNP of_IN TTP_NNP expression_NN by_IN LPS_NNP was_VBD subsequently_RB
          examined_VBN in_IN normal_JJ peripheral_JJ leukocytes_NNS ._. Whole_JJ blood_NN
          from_IN eight_CD healthy_JJ volunteers_NNS was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP alone_RB
          or_CC with_IN LPS_NNP (_( 0_CD ._. 1_LS μg_NN /_NN ml_NN )_) for_IN up_IN to_TO 24_CD hours_NNS ._. At_IN periodic_JJ
          time_NN points_NNS ,_, a_DT sample_NN was_VBD taken_VBN and_CC leukocytes_NNS were_VBD
          purified_JJ by_IN dextran_NN sedimentation_NN ,_, fixed_VBN ,_, permeabilized_JJ ,_,
          and_CC then_RB stained_JJ with_IN either_DT anti-_NN TTP_NNP or_CC control_NN
          antibody_NN ._. In_IN leukocytes_NNS ,_, constitutive_JJ expression_NN of_IN TTP_NNP
          ranged_VBD from_IN approximately_RB 9_CD ×_NN 10_CD 3_CD to_TO 35_CD ×_NN 10_CD 3_CD MESF_NNP ._.
          Monocytes_NNP constitutively_RB expressed_VBD over_IN three_CD times_NNS as_IN
          much_JJ TTP_NNP as_IN either_DT lymphocytes_NNS or_CC neutrophils_NNS (_( Table_NNP 1_LS )_) ._.
          Stimulation_NNP with_IN LPS_NNP 
          in_IN vitro_NN produced_VBD an_DT increase_NN in_IN
          TTP_NNP expression_NN in_IN all_DT leukocyte_NN subpopulations_NNS ._. This_DT was_VBD
          maximal_NN 2_CD hours_NNS after_IN stimulation_NN ._. TTP_NNP levels_NNS increased_VBN
          to_TO a_DT higher_JJR maximal_NN level_NN in_IN monocytes_NNS than_IN in_IN other_JJ
          leukocytes_NNS (_( +_NN 8_CD ._. 5_LS ×_NN 10_CD 3_CD MESF_NNP ;_: Fig_NNP ._. 3_LS a_DT )_) ._. Two-color_NNP flow_NN
          cytometry_NN indicated_VBD that_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN lymphocytes_NNS
          expressed_VBD equivalent_NN amounts_NNS of_IN TTP_NNP (_( data_NNS not_RB shown_VBN )_) ._. The_DT
          kinetics_NNS of_IN TTP_NNP induction_NN with_IN LPS_NNP was_VBD consistent_JJ and_CC
          monophasic_JJ in_IN all_DT leukocytes_NNS (_( Fig_NNP ._. 3_LS i_NNP )_) ._. The_DT change_NN in_IN TTP_NNP
          expression_NN was_VBD greatest_JJS in_IN neutrophils_NNS and_CC least_JJS in_IN
          lymphocytes_NNS ._. Since_IN lymphocytes_NNS lack_VBP Toll-like_NNP receptor_NN 4_CD
          and_CC express_VB little_JJ or_CC no_DT CD_NNP 14_CD [_NN 33_CD ]_NN ,_, we_PRP conclude_VBP that_IN
          the_DT induction_NN of_IN TTP_NNP in_IN these_DT cells_NNS was_VBD occurring_VBG
          indirectly_RB ,_, presumably_RB through_IN stimulation_NN with_IN TNF_NNP ,_,
          although_IN other_JJ cytokines_NNS ,_, including_VBG IL-_NNP 1_CD ,_, IL-_NNP 6_CD ,_, and_CC IL-_NNP 8_CD ,_,
          could_MD contribute_VB to_TO this_DT response_NN ._.
          LPS-induced_NNP TTP_NNP upregulation_NN was_VBD confirmed_VBN in_IN all_DT cell_NN
          types_NNS by_IN confocal_NN microscopy_NN ._. Analysis_NNP confirmed_VBD an_DT
          increase_NN in_IN TTP_NNP in_IN neutrophils_NNS 2_CD hours_NNS after_IN stimulation_NN
          (_( Fig_NNP ._. 3_LS )_) ._. Similar_JJ data_NNS were_VBD obtained_VBN for_IN lymphocytes_NNS and_CC
          monocytes_NNS (_( data_NNS not_RB shown_VBN )_) ._. Distribution_NN in_IN resting_VBG
          levels_NNS and_CC after_IN stimulation_NN with_IN LPS_NNP was_VBD primarily_RB
          cytosolic_JJ ,_, which_WDT is_VBZ in_IN accord_NN with_IN our_PRP$ data_NNS for_IN 293_CD and_CC
          THP-_NNP 1_CD cells_NNS ._.
        
        
          Correlation_NNP of_IN in_IN vivoTTP_NN production_NN with_IN TNF_NNP after_IN
          LPS_NNP bolus_JJ
          To_TO study_VB the_DT kinetics_NNS of_IN TTP_NNP induction_NN 
          in_IN vivo_NN ,_, we_PRP infused_VBN 4_CD ng_NN /_NN kg_NN of_IN
          clinical-grade_JJ endotoxin_NN at_IN time_NN 0_CD in_IN four_CD volunteers_NNS ._.
          Blood_NNP was_VBD drawn_VBN before_IN the_DT infusion_NN and_CC at_IN specified_VBN
          intervals_NNS afterwards_RB ,_, and_CC aliquots_NNS were_VBD analyzed_VBN for_IN
          leukocyte_NN cell_NN counts_VBZ ,_, TTP_NNP expression_NN ,_, and_CC plasma_NN TNF_NNP
          levels_NNS ._.
          The_DT cell_NN counts_NNS of_IN all_PDT the_DT leukocyte_NN subpopulations_NNS in_IN
          all_PDT the_DT volunteers_NNS fell_VBD rapidly_RB ,_, as_IN seen_VBN 1_CD hour_NN after_IN
          infusion_NN in_IN all_DT volunteers_NNS (_( Fig_NNP ._. 4_LS a_DT ,_, 4_CD b_SYM ,_, 4_CD c_SYM )_) ,_, in_IN
          concordance_NN with_IN published_VBN data_NNS [_NN 34_CD 35_CD 36_CD ]_NN ._. Beyond_IN the_DT
          1_CD -_: hour_NN time_NN point_NN ,_, the_DT neutrophil_NN cell_NN count_NN increased_VBD ,_,
          reaching_VBG a_DT peak_NN at_IN 12_CD hours_NNS ._. It_PRP then_RB decreased_VBD to_TO
          baseline_NN values_NNS at_IN 24_CD hours_NNS (_( Fig_NNP ._. 4_LS a_DT )_) ._. Lymphocyte_NNP and_CC
          monocyte_NN data_NNS showed_VBD similar_JJ initial_JJ kinetics_NNS ._. The_DT
          lymphocyte_NN and_CC monocyte_NN curves_NNS were_VBD biphasic_JJ ,_, peaking_VBG at_IN
          4_CD hours_NNS ,_, dropping_VBG to_TO baseline_NN at_IN 12_CD hours_NNS ,_, and_CC beginning_VBG
          a_DT second_JJ increase_NN at_IN 48_CD hours_NNS ._.
          Plasma_NNP TNF_NNP levels_NNS were_VBD analyzed_VBN throughout_IN the_DT study_NN ._.
          The_DT circulating_VBG TNF_NNP level_NN increased_VBD to_TO a_DT peak_NN at_IN 2_CD hours_NNS
          after_IN infusion_NN (_( Fig_NNP ._. 4_LS d_SYM )_) ._. After_IN 12_CD hours_NNS ,_, there_EX was_VBD no_DT
          detectable_JJ TNF_NNP in_IN any_DT of_IN the_DT four_CD volunteers_NNS ._. This_DT
          monophasic_JJ peak_NN was_VBD consistent_JJ with_IN findings_NNS in_IN other_JJ
          studies_NNS [_NN 37_CD ]_NN ._.
          Analysis_NNP of_IN TTP_NNP expression_NN in_IN leukocyte_NN populations_NNS
          before_IN and_CC after_IN LPS_NNP infusion_NN revealed_VBD a_DT biphasic_JJ
          induction_NN ,_, with_IN an_DT initial_JJ peak_NN occurring_VBG within_IN 4_CD hours_NNS
          and_CC a_DT second_NN after_IN 12_CD hours_NNS (_( Fig_NNP ._. 5_LS a_DT ,_, 5_CD b_SYM ,_, 5_CD c_SYM )_) ._. Baseline_NNP and_CC
          maximum_NN TTP_NNP expression_NN in_IN each_DT cell_NN type_NN for_IN each_DT
          volunteer_NN is_VBZ presented_VBN in_IN Table_NNP 2_CD ._. The_DT expression_NN and_CC
          initial_JJ upregulation_NN of_IN TTP_NNP in_IN response_NN to_TO LPS_NNP in_IN all_DT
          leukocyte_NN populations_NNS was_VBD consistent_JJ with_IN the_DT data_NNS found_VBD 
          in_IN vitro_NN ._. Neutrophils_NNP responded_VBD
          rapidly_RB to_TO LPS_NNP infusion_NN ,_, reaching_VBG an_DT initial_JJ peak_NN within_IN
          an_DT hour_NN of_IN infusion_NN ,_, although_IN the_DT average_JJ increase_NN in_IN the_DT
          four_CD volunteers_NNS appears_VBZ to_TO be_VB moderate_JJ (_( 50_CD %_NN )_) ._. Analysis_NNP of_IN
          monocytic_JJ TTP_NNP showed_VBD an_DT increase_NN in_IN expression_NN ,_, peaking_VBG
          at_IN 2_CD hours_NNS (_( Fig_NNP ._. 5_LS b_SYM )_) ._. Lymphocyte_NNP TTP_NNP expression_NN peaked_VBD at_IN
          4_CD hours_NNS ,_, which_WDT was_VBD later_RBR than_IN the_DT initial_JJ peak_NN response_NN
          of_IN neutrophils_NNS and_CC monocytes_NNS (_( Fig_NNP ._. 5_LS c_SYM )_) ._. A_DT second_NN ,_, more_RBR
          dramatic_JJ ,_, rise_NN ,_, which_WDT did_VBD not_RB parallel_JJ changes_NNS in_IN plasma_NN
          TNF_NNP levels_NNS (_( Fig_NNP ._. 5_LS d_SYM )_) ,_, was_VBD observed_VBN 12_CD hours_NNS after_IN
          infusion_NN in_IN all_DT leukocyte_NN populations_NNS ._.
        
        
          TNF_NNP contribution_NN in_IN LPS_NNP induction_NN of_IN TTP_NNP
          The_DT human_NN 
          in_IN vivo_NN studies_NNS described_VBD here_RB show_NN
          increases_NNS in_IN circulating_VBG plasma_NN TNF_NNP that_WDT preceded_VBN TTP_NNP
          induction_NN in_IN all_PDT the_DT leukocyte_NN types_NNS investigated_VBN ._. This_DT
          observation_NN is_VBZ consistent_JJ with_IN the_DT hypothesis_NNS that_IN LPS_NNP
          mediates_NNS induction_NN of_IN TTP_NNP through_IN the_DT production_NN of_IN TNF_NNP ._.
          However_RB ,_, this_DT hypothesis_NNS does_VBZ not_RB explain_VB the_DT second_JJ rise_NN
          in_IN TTP_NNP we_PRP observed_VBD 
          in_IN vivo_NN ,_, which_WDT was_VBD not_RB associated_VBN
          with_IN TNF_NNP ._. To_TO examine_VB this_DT phenomena_NNS in_IN more_JJR detail_NN ,_, THP-_NNP 1_CD
          cells_NNS were_VBD cultured_JJ with_IN LPS_NNP or_CC TNF_NNP in_IN the_DT presence_NN of_IN
          blocking_VBG TNF_NNP antibody_NN ._. The_DT antibody_NN sequesters_NNS TNF_NNP in_IN the_DT
          supernatant_NN ,_, preventing_VBG its_PRP$ interaction_NN with_IN TNF_NNP
          receptors_NNS ._. LPS_NNP induced_VBD greater_JJR TTP_NNP expression_NN than_IN TNF_NNP
          (_( Fig_NNP ._. 6_CD a_DT ,_, 6_CD b_SYM )_) ._. When_WRB THP-_NNP 1_CD cells_NNS were_VBD stimulated_VBN with_IN LPS_NNP
          in_IN the_DT presence_NN of_IN the_DT blocking_VBG TNF_NNP antibody_NN ,_, the_DT TTP_NNP
          response_NN was_VBD reduced_VBN but_CC not_RB eliminated_VBN (_( Fig_NNP ._. 6_CD a_DT )_) ._. In_IN
          fact_NN ,_, the_DT initial_JJ induction_NN of_IN TTP_NNP detectable_JJ during_IN the_DT
          first_JJ hour_NN was_VBD unaffected_JJ ,_, suggesting_VBG that_IN TNF_NNP was_VBD not_RB
          solely_RB responsible_JJ for_IN the_DT LPS-induced_NNP rise_NN ._. In_IN contrast_NN ,_,
          TNF_NNP induction_NN of_IN TTP_NNP by_IN THP-_NNP 1_CD cells_NNS was_VBD completely_RB
          blocked_VBN in_IN the_DT presence_NN of_IN the_DT blocking_VBG TNF_NNP antibody_NN
          (_( Fig_NNP ._. 6_CD b_SYM )_) ._.
        
      
      
        Discussion_NNP
        This_DT study_NN is_VBZ the_DT first_JJ to_TO evaluate_VB the_DT expression_NN and_CC
        regulation_NN of_IN endogenous_JJ human_JJ TTP_NNP in_IN myeloid_NN and_CC lymphoid_NN
        cells_NNS ._. It_PRP is_VBZ the_DT first_JJ to_TO examine_VB the_DT subcellular_NN
        localization_NN of_IN native_JJ TTP_NNP protein_NN in_IN freshly_RB isolated_VBN
        cells_NNS ,_, since_IN all_DT previous_JJ studies_NNS relied_VBN on_IN prolonged_JJ cell_NN
        culture_NN or_CC transfection_NN /_NN overexpression_NN approaches_NNS using_VBG
        cell_NN lines_NNS [_NN 20_CD 21_CD 22_CD 24_CD 25_CD ]_NN ._. We_PRP show_VBP that_IN endogenous_JJ
        human_JJ TTP_NNP is_VBZ expressed_VBN in_IN neutrophils_NNS ,_, lymphocytes_NNS ,_, and_CC
        monocytes_NNS ._. They_PRP are_VBP significant_JJ in_IN their_PRP$ demonstration_NN that_IN
        native_JJ human_JJ TTP_NNP is_VBZ totally_RB cytoplasmic_JJ ;_: there_EX was_VBD little_JJ
        evidence_NN of_IN nuclear_JJ localization_NN in_IN these_DT studies_NNS ,_, an_DT
        observation_NN that_WDT is_VBZ consistent_JJ with_IN previous_JJ work_NN with_IN
        human_JJ TTP_NNP ,_, in_IN which_WDT immunoblotting_VBG showed_VBN cytoplasmic_JJ
        localization_NN [_NN 24_CD ]_NN ._.
        The_DT discrepancy_NN between_IN our_PRP$ findings_NNS and_CC findings_NNS of_IN
        nuclear_JJ localization_NN of_IN TTP_NNP may_MD be_VB due_JJ to_TO several_JJ factors_NNS [_NN
        20_CD 21_CD 22_CD 24_CD 25_CD ]_NN ._. First_CD ,_, most_JJS of_IN those_DT studies_NNS did_VBD not_RB
        measure_VB endogenous_JJ TTP_NNP but_CC usually_RB relied_VBN on_IN transfection_NN
        of_IN cell_NN lines_NNS ,_, perhaps_RB resulting_VBG in_IN mislocalization_NN due_JJ to_TO
        the_DT presence_NN of_IN an_DT epitope_NN tag_NN or_CC overexpression_NN [_NN 20_CD 21_CD 22_CD
        24_CD 25_CD ]_NN ._. Second_JJ ,_, by_IN definition_NN ,_, those_DT cells_NNS were_VBD largely_RB
        cycling_NN and_CC thus_RB were_VBD not_RB representative_NN of_IN normal_JJ
        hematopoietic_JJ cells_NNS ._. Third_NNP ,_, mouse_NN or_CC rat_NN TTP_NNP was_VBD used_VBN in_IN
        those_DT studies_NNS [_NN 20_CD 21_CD 22_CD 25_CD ]_NN ._. Although_IN highly_RB conserved_JJ ,_,
        it_PRP is_VBZ possible_JJ that_IN human_JJ TTP_NNP is_VBZ subtly_RB different_JJ from_IN
        rodent_NN TTP_NNP ._. We_PRP think_VBP this_DT unlikely_JJ ,_, as_IN immunoprecipitation_NN
        studies_NNS of_IN bone-marrow-derived_JJ murine_NN macrophages_NNS show_VBP
        murine_NN TTP_NNP predominantly_RB in_IN the_DT cytoplasmic_JJ fraction_NN [_NN 23_CD ]_NN
        ._. This_DT matter_NN requires_VBZ further_JJ analysis_NN once_RB improved_VBD
        antibodies_NNS to_TO murine_NN TTP_NNP are_VBP generated_VBN ._.
        Our_PRP$ studies_NNS clearly_RB showed_VBD human_JJ TTP_NNP in_IN lymphocytes_NNS and_CC
        neutrophils_NNS ,_, in_IN addition_NN to_TO monocytes_NNS ._. Early_RB work_NN by_IN
        Carballo_NNP and_CC colleagues_NNS [_NN 38_CD ]_NN showed_VBD the_DT importance_NN of_IN
        macrophages_NNS ,_, not_RB lymphocytes_NNS ,_, in_IN the_DT development_NN of_IN the_DT
        phenotype_NN associated_VBN with_IN TTP_NNP deficiency_NN ._. This_DT highlights_VBZ
        the_DT importance_NN of_IN macrophages_NNS in_IN the_DT production_NN of_IN TNF_NNP ,_,
        supported_VBN by_IN current_JJ hypotheses_NNS on_IN the_DT pivotal_JJ role_NN of_IN this_DT
        cell_NN type_NN in_IN TNF_NNP overproduction_NN in_IN autoimmune_JJ diseases_NNS [_NN 39_CD
        ]_NN ._. Thus_RB ,_, our_PRP$ findings_NNS suggest_VBP that_IN TTP_NNP serves_VBZ an_DT entirely_RB
        different_JJ role_NN in_IN other_JJ leukocytes_NNS ,_, relative_JJ to_TO their_PRP$ role_NN
        in_IN regulating_VBG cytokine_NN production_NN by_IN macrophages_NNS ,_, and_CC that_IN
        TNF_NNP production_NN is_VBZ not_RB simply_RB regulated_VBN by_IN TTP_NNP ._.
        Despite_IN these_DT potential_JJ differences_NNS in_IN the_DT function_NN of_IN
        human_JJ TTP_NNP based_VBN on_IN cell_NN type_NN ,_, our_PRP$ studies_NNS show_VBP a_DT common_JJ
        pattern_NN of_IN induction_NN by_IN LPS_NNP in_IN monocytes_NNS ,_, neutrophils_NNS ,_, and_CC
        lymphocytes_NNS ._. The_DT upregulation_NN of_IN human_JJ TTP_NNP occurs_VBZ rapidly_RB ,_,
        within_IN the_DT first_JJ hour_NN of_IN stimulation_NN ._. This_DT is_VBZ consistent_JJ
        with_IN murine_NN data_NNS demonstrating_VBG that_DT upregulation_NN occurs_VBZ
        within_IN 30_CD min_NN of_IN LPS_NNP stimulation_NN ,_, remaining_VBG high_JJ for_IN 4_CD
        hours_NNS [_NN 23_CD ]_NN ._. Using_VBG confocal_NN imaging_NN ,_, we_PRP found_VBD TTP_NNP was_VBD
        primarily_RB detected_VBN in_IN the_DT cytoplasmic_JJ fraction_NN ,_, confirming_VBG
        our_PRP$ earlier_JJR immunoblotting_VBG studies_NNS [_NN 24_CD ]_NN ._.
        LPS_NNP stimulation_NN of_IN peripheral_JJ blood_NN leukocytes_NNS 
        in_IN vitro_NN revealed_VBD TTP-induction_NNP
        kinetics_NNS analogous_JJ to_TO that_DT observed_VBD for_IN THP-_NNP 1_CD cells_NNS ._. We_PRP
        used_VBD a_DT whole_JJ blood_NN assay_NN ,_, since_IN the_DT cytokines_NNS produced_VBN
        after_IN 
        in_IN vitro_NN incubation_NN with_IN LPS_NNP are_VBP
        analogous_JJ to_TO those_DT produced_VBN after_IN 
        in_IN vivo_NN infusion_NN ,_, providing_VBG an_DT
        important_JJ model_NN of_IN sepsis_NN [_NN 40_CD ]_NN ._. Baseline_NNP expression_NN of_IN
        TTP_NNP was_VBD higher_JJR in_IN monocytes_NNS than_IN in_IN either_DT lymphocytes_NNS or_CC
        neutrophils_NNS ._. Lymphocytes_NNP responded_VBD the_DT least_JJS to_TO LPS_NNP
        stimulation_NN ,_, whereas_IN monocytes_NNS responded_VBD the_DT most_JJS ._.
        Monocytes_NNP were_VBD not_RB followed_VBN beyond_IN 4_CD hours_NNS after_IN
        stimulation_NN with_IN LPS_NNP ,_, because_IN of_IN the_DT low_JJ numbers_NNS of_IN cells_NNS
        retrieved_VBD ,_, probably_RB due_JJ to_TO upregulation_NN of_IN adhesion_NN
        molecules_NNS (_( ICAM-_NNP 1_LS )_) [_NN 41_CD ]_NN ._.
        The_DT induction_NN of_IN TTP_NNP expression_NN by_IN either_DT LPS_NNP or_CC TNF_NNP has_VBZ
        not_RB been_VBN studied_VBN in_IN an_DT 
        in_IN vivo_NN system_NN before_RB ._. In_IN this_DT study_NN ,_,
        four_CD human_JJ volunteers_NNS were_VBD infused_VBN with_IN LPS_NNP and_CC the_DT
        subsequent_JJ changes_NNS in_IN leukocyte_NN cell_NN count_NN ,_, TTP_NNP expression_NN
        in_IN leukocyte_NN subpopulations_NNS ,_, and_CC levels_NNS of_IN TNF_NNP were_VBD
        followed_VBN over_IN a_DT 72_CD -_: hour_NN period_NN ._. Although_IN there_EX was_VBD some_DT
        individual_JJ variability_NN in_IN the_DT overall_JJ kinetics_NNS ,_, basal_NN
        levels_NNS and_CC the_DT initial_JJ induction_NN of_IN TTP_NNP by_IN LPS_NNP were_VBD within_IN
        the_DT range_NN observed_VBD 
        in_IN vitro_NN (_( Tables_NNP 1_CD and_CC 2_LS )_) ._. All_DT cell_NN
        types_NNS showed_VBD an_DT increase_NN in_IN TTP_NNP expression_NN within_IN the_DT first_JJ
        hour_NN ._. Interestingly_RB ,_, TTP_NNP was_VBD induced_VBN by_IN LPS_NNP 
        in_IN vivo_NN more_RBR slowly_RB (_( after_IN 4_CD hours_NNS vs_NNS
        1_CD -_: 2_CD hours_NNS )_) and_CC to_TO a_DT lesser_JJR degree_NN in_IN the_DT lymphocyte_NN
        population_NN than_IN in_IN neutrophils_NNS or_CC monocytes_NNS ._. The_DT absence_NN of_IN
        LPS-signal_NNP transducers_NNS (_( CD_NNP 14_CD ,_, Toll-like_NNP receptor_NN 4_LS )_) on_IN most_JJS
        lymphocytes_NNS relative_JJ to_TO monocytes_NNS and_CC neutrophils_NNS may_MD
        account_VB for_IN this_DT altered_JJ expression_NN [_NN 42_CD 43_CD ]_NN ._. Since_IN
        lymphocytes_NNS express_VBP TNF_NNP receptors_NNS and_CC TNF_NNP itself_PRP can_MD induce_VB
        TTP_NNP mRNA_NN expression_NN [_NN 38_CD ]_NN ,_, these_DT data_NNS are_VBP consistent_JJ with_IN
        the_DT interpretation_NN that_IN TTP_NNP induction_NN in_IN lymphocytes_NNS is_VBZ
        transduced_JJ not_RB by_IN LPS_NNP binding_JJ ,_, but_CC by_IN TNF_NNP produced_VBN by_IN
        monocytes_NNS and_CC /_NN or_CC neutrophils_NNS acting_VBG on_IN lymphocytes_NNS ._.
        The_DT initial_JJ fall_NN in_IN leukocyte_NN cell_NN count_NN observed_VBD 
        in_IN vivo_NN is_VBZ in_IN accord_NN with_IN published_VBN
        data_NNS [_NN 34_CD 35_CD 36_CD ]_NN ._. The_DT numbers_NNS of_IN monocytes_NNS and_CC
        neutrophils_NNS dropped_VBD within_IN the_DT first_JJ hour_NN ,_, by_IN approximately_RB
        98_CD %_NN and_CC 76_CD %_NN ,_, respectively_RB ,_, and_CC of_IN lymphocytes_NNS ,_, by_IN 80_CD %_NN after_IN
        4_CD hours_NNS ._. This_DT decrease_NN is_VBZ consistent_JJ with_IN data_NNS suggesting_VBG
        that_IN the_DT reduction_NN in_IN leukocytes_NNS results_NNS from_IN a_DT decrease_NN in_IN
        granulocytes_NNS and_CC monocytes_NNS as_IN they_PRP become_VBP activated_VBN ,_,
        migrating_VBG and_CC adhering_VBG to_TO vascular_NN endothelium_NN [_NN 44_CD ]_NN ._.
        This_DT drop_NN in_IN cell_NN numbers_NNS was_VBD followed_VBN by_IN an_DT increase_NN in_IN
        all_DT leukocyte_NN populations_NNS ,_, beginning_VBG at_IN 12_CD hours_NNS and_CC
        continuing_VBG through_IN the_DT 72_CD -_: hour_NN time_NN point_NN ._. This_DT raises_VBZ the_DT
        issue_NN of_IN whether_IN the_DT apparent_JJ changes_NNS in_IN TTP_NNP expression_NN
        were_VBD due_JJ ,_, in_IN part_NN ,_, to_TO differential_NN rates_NNS of_IN margination_NN by_IN
        leukocyte_NN subpopulations_NNS ._. Since_IN the_DT levels_NNS of_IN TTP_NNP induction_NN
        seen_VBN in_IN the_DT first_JJ hour_NN 
        in_IN vivo_NN approximate_JJ those_DT seen_VBN 
        in_IN vitro_NN ,_, we_PRP believe_VBP that_IN this_DT
        induction_NN reflects_VBZ the_DT increased_VBN synthesis_NN and_CC expression_NN
        of_IN TTP_NNP by_IN all_DT leukocyte_NN subpopulations_NNS and_CC is_VBZ consistent_JJ
        with_IN the_DT kinetics_NNS of_IN their_PRP$ mRNA_NN induction_NN [_NN 23_CD ]_NN ._.
        TTP_NNP and_CC TNF_NNP are_VBP reportedly_RB involved_VBN in_IN a_DT
        negative-feedback_JJ loop_NN ,_, in_IN which_WDT increases_NNS in_IN TNF_NNP
        concentration_NN are_VBP associated_VBN with_IN induction_NN of_IN TTP_NNP [_NN 23_CD ]_NN ._.
        In_IN these_DT studies_NNS ,_, LPS_NNP ,_, which_WDT induces_VBZ the_DT release_NN of_IN TNF_NNP [_NN
        45_CD ]_NN ,_, produced_VBD a_DT rise_NN in_IN TTP_NNP within_IN 4_CD hours_NNS of_IN
        stimulation_NN ._. Although_IN the_DT initial_JJ rise_NN in_IN TTP_NNP 
        in_IN vivo_NN paralleled_JJ a_DT rapid_JJ and_CC
        considerable_JJ increase_NN in_IN plasma_NN TNF_NNP ,_, the_DT second_JJ ,_, late_JJ
        increases_NNS in_IN intracellular_NN TTP_NNP did_VBD not_RB reflect_VB TNF_NNP levels_NNS ._.
        This_DT change_NN may_MD have_VB been_VBN mediated_JJ by_IN other_JJ cytokines_NNS
        (_( IL-_NNP 1_CD β_NN ,_, IL-_NNP 8_CD )_) whose_WP$ levels_NNS have_VBP been_VBN shown_VBN to_TO increase_VB with_IN
        kinetics_NNS that_IN parallel_VB this_DT rise_NN in_IN TTP_NNP [_NN 40_CD 46_CD 47_CD ]_NN ._.
        Alternatively_RB ,_, the_DT late_JJ rise_NN in_IN cytoplasmic_JJ TTP_NNP may_MD be_VB due_JJ
        to_TO release_VB from_IN the_DT bone_NN marrow_NN of_IN leukocytes_NNS that_WDT have_VBP
        high_JJ levels_NNS of_IN TTP_NNP or_CC an_DT adaptive_JJ response_NN to_TO
        endotoxemia_NN ._.
        TNF_NNP overproduction_NN mediates_NNS both_DT sepsis_NN and_CC chronic_JJ
        inflammatory_JJ disorders_NNS such_JJ as_IN RA_NNP ._. Its_PRP$ production_NN may_MD be_VB
        modulated_JJ at_IN transcriptional_NN ,_, post-transcriptional_JJ ,_, and_CC
        post-translational_JJ levels_NNS [_NN 48_CD 49_CD 50_CD ]_NN ._. Many_JJ of_IN the_DT
        effects_NNS observed_VBD after_IN LPS_NNP stimulation_NN can_MD be_VB attributed_VBN to_TO
        subsequent_JJ production_NN of_IN TNF_NNP ._. Moreover_RB ,_, infusion_NN of_IN TNF_NNP
        initiates_NNS inflammatory_JJ processes_NNS ,_, with_IN a_DT resulting_VBG
        phenotype_NN that_WDT is_VBZ indistinguishable_JJ from_IN bacterial_JJ sepsis_NN [_NN
        13_CD 14_CD ]_NN ._. We_PRP investigated_VBD the_DT contribution_NN of_IN TNF_NNP in_IN the_DT
        LPS-mediated_NNP induction_NN of_IN TTP_NNP in_IN THP-_NNP 1_CD cells_NNS using_VBG a_DT
        blocking_VBG TNF_NNP antibody_NN ._. TNF_NNP induction_NN of_IN TTP_NNP expression_NN was_VBD
        almost_RB completely_RB eliminated_VBN by_IN incubation_NN with_IN the_DT TNF_NNP
        inhibitor_NN ,_, proving_VBG the_DT direct_JJ effect_NN of_IN TNF_NNP on_IN TTP_NNP
        induction_NN ._. LPS_NNP ,_, however_RB ,_, induced_VBD much_RB greater_JJR levels_NNS of_IN TTP_NNP
        in_IN THP-_NNP 1_CD cells_NNS than_IN TNF_NNP did_VBD ._. In_IN the_DT presence_NN of_IN blocking_VBG
        TNF_NNP antibody_NN ,_, LPS_NNP induction_NN of_IN TTP_NNP was_VBD initially_RB unaffected_JJ
        but_CC began_VBD to_TO decline_VB after_IN 1_CD hour_NN ,_, suggesting_VBG that_IN LPS_NNP
        itself_PRP may_MD mediate_VB the_DT initial_JJ increases_NNS in_IN TTP_NNP and_CC showing_VBG
        that_IN the_DT prolonged_JJ induction_NN of_IN TTP_NNP is_VBZ dependent_JJ on_IN
        TNF_NNP ._.
      
      
        Conclusion_NNP
        We_PRP have_VBP shown_VBN through_IN an_DT intracellular_NN staining_VBG assay_NN
        that_IN human_JJ TTP_NNP expression_NN is_VBZ modulated_JJ by_IN LPS_NNP and_CC TNF_NNP ._.
        LPS-induction_NNP of_IN TTP_NNP was_VBD partly_RB dependent_JJ on_IN the_DT production_NN
        of_IN TNF_NNP ._. The_DT ability_NN of_IN LPS_NNP to_TO induce_VB TTP_NNP independently_RB of_IN
        TNF_NNP may_MD account_VB for_IN the_DT earlier_JJR response_NN observed_VBD in_IN
        neutrophils_NNS and_CC monocytes_NNS that_WDT have_VBP LPS-signaling_NNP
        transduction_NN molecules_NNS ._. In_IN contrast_NN ,_, lymphocytes_NNS
        demonstrate_VBP a_DT delayed_VBN and_CC lower_JJR TTP_NNP response_NN and_CC are_VBP
        probably_RB responding_VBG to_TO TNF_NNP ,_, or_CC other_JJ cytokines_NNS ,_, produced_VBN by_IN
        myeloid_NN cells_NNS ._. In_IN addition_NN ,_, a_DT second_JJ rise_NN in_IN TTP_NNP expression_NN
        was_VBD observed_VBN 
        in_IN vivo_NN ,_, which_WDT did_VBD not_RB correlate_VBP
        with_IN any_DT detectable_JJ rise_NN in_IN TNF_NNP concentration_NN ,_, implying_VBG
        that_IN there_EX are_VBP additional_JJ factors_NNS involved_VBN in_IN the_DT
        regulation_NN of_IN this_DT intracellular_NN protein_NN ._. TNF_NNP is_VBZ a_DT
        predominant_NN proinflammatory_NN cytokine_NN ,_, particularly_RB in_IN
        sepsis_NN and_CC chronic_JJ inflammatory_JJ disorders_NNS suggesting_VBG that_IN
        the_DT role_NN of_IN its_PRP$ negative_JJ regulator_NN ,_, TTP_NNP ,_, may_MD be_VB of_IN
        functional_JJ importance_NN in_IN the_DT development_NN and_CC pathogenesis_NNS
        of_IN disease_NN ._. Investigating_VBG any_DT potential_JJ abnormalities_NNS in_IN
        expression_NN or_CC regulation_NN may_MD prove_VB to_TO be_VB a_DT valuable_JJ
        therapeutic_JJ intervention_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        APC_NNP =_SYM allophycocyanin_NN ;_: ARE_VBP =_SYM AU-rich_NNP element_NN ;_: CM_NNP =_SYM
        complete_JJ media_NNS ;_: ELISA_NNP =_SYM enzyme-linked_JJ immunosorbent_NN assay_NN ;_:
        FACS_NNP =_SYM fluorescence-activated_JJ cell_NN sorting_VBG ;_: FITC_NNP =_SYM
        fluorescein_NN isothiocyanate_NN ;_: IL_NNP =_SYM interleukin_NN ;_: KLH_NNP =_SYM keyhole_NN
        limpet_NN hemocyanin_NN ;_: LPS_NNP =_SYM lipopolysaccharide_NN ;_: MESF_NNP =_SYM
        milliequivalents_NNS of_IN soluble_JJ fluorescein_NN ;_: RPMI_NNP =_SYM Roswell_NNP
        Park_NNP Memorial_NNP Institute_NNP [_NN medium_NN ]_NN ;_: RT-PCR_NNP =_SYM reverse_VB
        transcriptase_NN polymerase_NN chain_NN reaction_NN ;_: TNF_NNP =_SYM tumor_NN
        necrosis_NNS factor_NN ;_: TNFR_NNP =_SYM TNF_NNP receptor_NN ;_: TTP_NNP =_SYM
        tristetraprolin_NN ;_: WBC_NNP =_SYM white_JJ blood_NN cell_NN ._.
      
    
  
